Anshen Buxin Liuwei Pill improves cardiac neurosis symptoms, anxiety, depression, and sleep quality in patients with heyisheng-type palpitation
In a randomized, double-blind, placebo-controlled trial, Anshen Buxin Liuwei Pill significantly improved cardiac neurosis symptoms (effective rate 83.00% vs 34.80% at week 8) and showed longer-term benefits in anxiety, depression, and sleep quality. The drug was safe and well-tolerated.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Anshen Buxin Liuwei Pill improves cardiac neurosis symptoms, anxiety, depression, and sleep quality in patients with heyisheng-type palpitation The current body of evidence comprises 1 study, including 1 randomized controlled trial. EvidenceHub rates the overall confidence at 44/100 (low).
The Claim
Anshen Buxin Liuwei Pill improves cardiac neurosis symptoms, anxiety, depression, and sleep quality in patients with heyisheng-type palpitation
This conclusion is most relevant to: Patients with cardiac neurosis (heyisheng-type palpitation), n=182.
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Anshen Buxin Liuwei Pill for the treatment of cardiac neurosis (heyisheng-type palpitation): a randomized, double-blind clinical trial. (Journal of thoracic disease, 2026) —
How It Works
The proposed biological pathway:
- ▸Anshen Buxin Liuwei Pill acts on cardiac neurosis symptoms
- ▸It alleviates anxiety and depression
- ▸It improves sleep quality
- ▸Result: Significant clinical improvement in symptoms and mood/sleep scores
Who Might Benefit
Evidence fit by population:
- ▸Patients with cardiac neurosis (heyisheng-type palpitation), n=182
Recommended Dose
Not specified
Limitations & Caveats
Important context when interpreting this evidence:
- ▸No significant differences in hs-CRP and 5-HT between groups, suggesting unclear biological mechanism
- ▸High dropout rate (9 per group) may affect results
- ▸Single-center trial with specific population (Mongolian medicine context) may limit generalizability
Frequently Asked Questions
What is the effective rate of Anshen Buxin Liuwei Pill for cardiac neurosis?▼
At week 8, the effective rate was 83.00% (95% CI: 75.32-90.68%) in the treatment group versus 34.80% (95% CI: 25.07-44.53%) in the placebo group.
Does Anshen Buxin Liuwei Pill improve sleep quality?▼
Yes, the trial reported longer-term benefits in sleep quality, with significantly better sleep scores at weeks 2, 8, and 12 compared to placebo.
What is the study design and sample size?▼
It is a randomized, double-blind, placebo-controlled trial with 182 participants (91 per group) who received 8 weeks of treatment and were followed up to week 12.
Are there any side effects?▼
The study reported a favorable safety profile, with no significant adverse events attributed to the drug; one dropout in the control group was related to hypertension adverse event.
References
- 1.Lan Y, Zheng C, Liu J, Nashun D, Ma J, Li G, Yin G, Ma L. “Anshen Buxin Liuwei Pill for the treatment of cardiac neurosis (heyisheng-type palpitation): a randomized, double-blind clinical trial..” Journal of thoracic disease, 2026. PMID: 42583339 DOI: 10.21037/jtd-2026-1612